Why the study?
Important differences exist between oral and intravenous amiodarone administration regarding hemodynamics, pharmacokinetics, electrophysiology, and antiarrhythmic efficacy.
What are the hemodynamic, pharmacokinetic, electrophysiological effects, and clinical utility of intravenous amiodarone compared to oral administration?
What are the hemodynamic, pharmacokinetic, electrophysiological effects, and clinical utility of intravenous amiodarone compared to oral administration?
Intravenous amiodarone is a highly effective agent for refractory life-threatening arrhythmias, though its unique hemodynamic, pharmacokinetic, and electrophysiological properties require careful management in critical care settings.
Answers are grounded in this paper and cite their sources.
Mandates route-specific hemodynamic monitoring with amiodarone; challenges interchangeable use between oral and IV formulations in practice and research.
M ostow ND, E t A l : Intravenous amiodarone: Hemodynamics, pharmacokinetics, electophysiology, and clinical utility . Amiodarone, administered orally or intravenously, is extremely effective for the suppression of a wide variety of supraventricular and ventricular arrhythmias. However, important differences have been observed between these modes of administration in hemodynamic effects, pharmacokinetic distribution, electrophysiological actions, and antiarrhythmic efficacy. In contrast with oral amiodarone, intravenous administration causes a fall in systemic vascular resistance and, particularly in patients with impaired ventricular performance, a decrease in contractility. The pharmacokinetic distribution of intravenous amiodarone is multicompartmental, with large amounts of drug distributing into tissues at different rates during the first few days of therapy. The electrophysiological effects of intravenous amiodarone, measured within minutes of drug administration, occur primarily at the sinus and atrioventricular nodes, whereas the electrophysiological actions of chronic amiodarone therapy involve a dramatic Prolongation of the refractory periods of atrial and ventricular muscle tissues. Intravenous amiodarone is useful to interrupt a variety of supraventricular tachycardias and will reliably slow the ventricular response to atrial fibrillation and flutter. In recent work, intravenous amiodarone has shown remarkable efficacy in the control of immediately life‐threatening ventricular tachycardia and ventricular fibrillation refractory to conventional agents including bretylium. While amiodarone's use engenders pharmacological complexities previously not encountered with cardiac drugs, its tremendous promise as an intravenous agent which can be followed with oral therapy mandates intense study of its utility in critical care settings .
No takes yet. Share an insight, caveat, or question.
Mostow et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: